AbbVie

Brain and money connected by a thread on a white background

Biotech

AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program

AbbVie has written the next chapter in its quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate for up to $1.2 billion.

Nick Paul Taylor Aug 25, 2025 9:42am

amyloid plaque alzheimers brain

Denali Alzheimer's antibody clears plaques without ARIA in mice

Aug 7, 2025 2:00pm

acquisition merger arrows

AbbVie ends development of IL-1 asset in ulcerative colitis

Jul 31, 2025 12:32pm

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

Question

AbbVie in talks over $1B Gilgamesh buyout: report

Jul 31, 2025 7:48am

Three blocks displaying from left to right a person a handshake and another person

AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer

Jul 10, 2025 9:01am